Cargando…
Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma
PURPOSE: To date, there has not been a large, systematic evaluation of the prevalence of germline risk variants in urothelial carcinoma (UC). METHODS: We evaluated the frequency of germline pathogenic and likely pathogenic variants in 1038 patients with high-risk UC who underwent targeted clinical g...
Autores principales: | Nassar, Amin H., Abou Alaiwi, Sarah, AlDubayan, Saud H., Moore, Nicholas, Mouw, Kent W., Kwiatkowski, David J., Choueiri, Toni K., Curran, Catherine, Berchuck, Jacob E., Harshman, Lauren C., Nuzzo, Pier V., Chanza, Nieves Martinez, Van Allen, Eliezer, Esplin, Edward D., Yang, Shan, Callis, Thomas, Garber, Judy E., Rana, Huma Q., Sonpavde, Guru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118025/ https://www.ncbi.nlm.nih.gov/pubmed/31844177 http://dx.doi.org/10.1038/s41436-019-0720-x |
Ejemplares similares
-
Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors
por: Nuzzo, Pier Vitale, et al.
Publicado: (2020) -
CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer
por: Adib, Elio, et al.
Publicado: (2021) -
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
por: Nassar, Amin H., et al.
Publicado: (2019) -
FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma
por: Adib, Elio, et al.
Publicado: (2021) -
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma
por: Abou Alaiwi, Sarah, et al.
Publicado: (2020)